EpiSign and Geneyx Integrated Genomic Analysis Tools
The companies formed a new partnership to combine genomic and epigenomic data in a single diagnostic workflow.
Updated on Oct. 5, 2026 in Diseases — General
Live Poll
Do you believe partnerships between diagnostic firms improve the quality of patient care?
EpiSign and Geneyx have announced a collaboration to integrate DNA methylation episignature analysis with Geneyx genomic and multi-omics software. This partnership aims to help clinical laboratories resolve rare-disease cases more efficiently by streamlining data analysis.
Why it matters
The collaboration is designed to reduce laboratory testing costs and shorten the diagnostic timeline for patients. By incorporating epigenomic evidence alongside genomic and phenotypic information in one workflow, the system works to eliminate the need for sequential testing.
EpiSign METRIC automates analysis for over 300 conditions and supports multiple sequencing platforms, including Illumina 5-base, PacBioHiFi, and Oxford Nanopore. The platform is currently designated for research use only.
The players
EpiSign
This biotechnology company is based in London, Ontario, and specializes in DNA methylation episignature analysis.
Geneyx
Headquartered in Herzliya, Israel, this firm provides genomic and multi-omics software capabilities for clinical laboratories.
The details
The integration allows laboratories to generate both genomic and epigenomic insights from a single assay. EpiSign METRIC is now available to Geneyx customers to assist in complex rare-disease diagnostics.
Timeline
EpiSign and Geneyx announced their partnership on October 5, 2026.
The Big Picture
This partnership follows the broader industry shift toward integrating multi-omics data in clinical diagnostic workflows to improve diagnostic yields. It marks a transition from sequential testing to consolidated analysis models for rare diseases.
Patients may experience shorter diagnostic timelines as laboratories adopt integrated workflows that reduce the need for sequential testing. These advancements support more efficient identification of rare conditions by clinicians.
The takeaway
Integrated genomic and epigenomic platforms represent a significant efficiency gain for complex disease diagnostics. Laboratories can now leverage automated analysis to potentially replace multi-step testing procedures.
Further reading
Learn more about the latest innovations in Diseases — General to understand how these tools impact diagnostic outcomes.
Live Poll
Do you believe partnerships between diagnostic firms improve the quality of patient care?
